Charles River extends gene therapy manufacturing alliance with NUS Yong Loo Lin School of Medicine in Singapore
US, March 21 -- based Charles River Laboratories International, Inc. and National University of Singapore's (NUS) Yong Loo Lin School of Medicine have announced a High Quality (HQ) plasmid DNA development and manufacturing agreement.
NUS Medicine will utilise Charles River's market leading contract development and manufacturing organisation (CDMO) expertise in HQ and GMP- compliant plasmid DNA, which serves as a critical starting material for its engineered stem cell cancer therapy and builds on a historic provision of research grade plasmid. NUS Medicine will leverage this collaboration to access Charles River's center of excellence, and established manufacturing platform, eXpDNA.
In recent years, Charles River has significantly expand...
Click here to read full article from source
To read the full article or to get the complete feed from this publication, please
Contact Us.